Oncotelic Therapeutics, Inc. (OTCQB: OTLC) has announced the completion of key Phase 2 objectives in its manufacturing automation initiative with TechForce Robotics, marking a significant step toward commercializing an AI-powered good manufacturing practices (GMP) manufacturing services platform at SAPU Bio, the company’s 45%-owned sterile injectable cGMP manufacturing joint venture. The Phase 2 deployment expands the capabilities of Oncotelic’s proprietary PDAOAI(TM) platform across sterile manufacturing operations, electronic batch records, GMP workflow execution, cleanroom monitoring and autonomous materials movement.
The integrated platform combines PDAOAI(TM) with TechForce’s autonomous robotic systems to support intelligent pharmaceutical manufacturing, creating potential opportunities in software licensing, automation deployment, manufacturing partnerships and technology-enabled contract development and manufacturing services. Oncotelic plans to demonstrate the platform at the BIO International Convention 2026 in San Diego as it pursues broader commercialization efforts within the pharmaceutical manufacturing sector. For more details, visit https://nnw.fm/j1n43.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on developing oncology and immunotherapy products for high-unmet-need cancers and rare pediatric indications. The company leverages its proprietary AI-enabled PDAOAI platform, which supports research, biomarker discovery, and regulatory processes through advanced data analysis and knowledge integration. Beyond its internal programs, Oncotelic licenses and co-develops select drug candidates through strategic partnerships and joint ventures, including its 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates. For the latest news and updates relating to OTLC, visit the company’s newsroom at https://nnw.fm/OTLC.
The completion of Phase 2 objectives represents a critical milestone for Oncotelic, as it moves closer to offering a fully integrated, AI-driven manufacturing solution that could significantly improve efficiency, compliance, and scalability in sterile pharmaceutical production. This advancement not only positions the company to potentially generate revenue through software licensing and automation services but also strengthens its overall value proposition in the competitive biopharmaceutical landscape. The upcoming demonstration at the BIO International Convention 2026 will provide a platform to showcase these capabilities to a global audience of industry leaders and potential partners.
